Abstract
A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): Acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.
| Language | English (US) |
|---|---|
| Pages | 1185-1192 |
| Number of pages | 8 |
| Journal | Pancreas |
| Volume | 47 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- acute pancreatitis
- drug therapy
- molecular targets
- trials
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology
Cite this
Accelerating the drug delivery pipeline for acute and chronic pancreatitis : Summary of the working group on drug development and trials in acute pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases workshop. / Abu-El-Haija, Maisam; Gukovskaya, Anna S.; Andersen, Dana; Gardner, Timothy B.; Hegyi, Peter; Pandol, Stephen J.; Papachristou, Georgios I.; Saluja, Ashok K.; Singh, Vikesh K.; Uc, Aliye; Wu, Bechien U.
In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1185-1192.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Accelerating the drug delivery pipeline for acute and chronic pancreatitis
T2 - Pancreas
AU - Abu-El-Haija, Maisam
AU - Gukovskaya, Anna S.
AU - Andersen, Dana
AU - Gardner, Timothy B.
AU - Hegyi, Peter
AU - Pandol, Stephen J.
AU - Papachristou, Georgios I.
AU - Saluja, Ashok K.
AU - Singh, Vikesh K.
AU - Uc, Aliye
AU - Wu, Bechien U.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): Acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.
AB - A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): Acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.
KW - acute pancreatitis
KW - drug therapy
KW - molecular targets
KW - trials
UR - http://www.scopus.com/inward/record.url?scp=85055080940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055080940&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001175
DO - 10.1097/MPA.0000000000001175
M3 - Article
VL - 47
SP - 1185
EP - 1192
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 10
ER -